Albuquerque's Western Dermatology Consultants Nominated in Local Top 5 Best Medical Spas

ALBUQUERQUE, NM—(Marketwired – October 27, 2017) – Well–known Albuquerque dermatology practice Western Dermatology Consultants has recently been nominated into this year's top five medical spas in the city by local publication Albuquerque The Magazine — and with good reason.

Its team of experienced, board–certified dermatologists, licensed nurses, physician assistants, and aestheticians have been offering a wide array of medical and cosmetic dermatological treatments in a relaxing, comfortable spa for nearly two decades. The practice prides itself on tailoring its services to enhance the health and appearance of patients' skin, hair, and nails in a New Mexico desert environment.

Medical concerns such as skin cancer, acne and scarring, dry skin, and nail fungus are appropriately diagnosed and treated with the highest standards of care. Mohs surgery, a modern surgical method to remove basal and squamous (non–melanoma) cancerous cells, is performed with great care to maximize cosmetic results, making the option particularly apt for areas such as the face, neck, and hands.

Injectable treatments target specific concerns on the face. The practice stocks neuromodulators such as BOTOX® Cosmetic that fight wrinkles created on the face from repeated muscle contractions over time (also known as dynamic wrinkles), as well as the entire line of Juvederm® fillers, each of which varies in formulation and are approved to treat specific areas.

Such treatments also garner favor with younger patients, who come into the practice for BOTOX® to prevent signs of aging before they begin, and filler to augment their cheeks and lips. BOTOX® is also used for more than just wrinkles – patients who suffer from hyperhidrosis, or excessive sweating, find relief in the treatment.

Skin tightening and hair, fat, and cellulite reduction treatments at Western Dermatology are popular over the winter and spring months to de–fuzz, sculpt, and tone the body in time for summer. These include Kybella® (submental fat under the chin), CoolSculpting®, VelaShape®, Thermage®, and laser hair removal.

Many patients also visit the practice looking for comprehensive, non–invasive solutions to address several skin concerns simultaneously, and the practice has a number of lasers for rejuvenating the skin deeply with minimal downtime.

For regular maintenance, rejuvenating treatments such as chemical peels, microdermabrasion, and facials, as well as application of LATISSE® eyelash serum and permanent makeup, are offered in consultation with the practice's dermatologists to maximize results, making them distinct from the services offered at most typical salons (which often offer no medical supervision in tandem).

To learn more or request a consultation, contact Western Dermatology Consultants online or call 505–855–9267.

Sirona Biochem Announces Resignation of Board Director

VANCOUVER, BC—(Marketwired – October 27, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today the resignation of Mr. David Moore from the board of directors due to conflicting commitments.

“We are very thankful to Mr. Moore for his contributions and guidance during his time on our board and wish him much success in his new position,” said Dr. Howard Verrico, CEO. “At this time the Company will remain with a vacancy on the board until a suitable replacement is found.”

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward–looking statements. Forward–looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward–looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward–looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward–looking statements except as required by law.